{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:51Z","timestamp":1785842271506,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clon.2018.04.006","type":"journal-article","created":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T23:36:36Z","timestamp":1525649796000},"page":"493-497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["When should Surgery be used for Recurrent Ovarian Carcinoma?"],"prefix":"10.1016","volume":"30","author":[{"given":"M.","family":"Bommert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.clon.2018.04.006_bib1","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clon.2018.04.006_bib3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9375","key":"10.1016\/j.clon.2018.04.006_bib4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.clon.2018.04.006_bib5","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.clon.2018.04.006_bib6","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2018.04.006_bib7","author":"Coleman","year":"2015"},{"issue":"8","key":"10.1016\/j.clon.2018.04.006_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clon.2018.04.006_bib9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.clon.2018.04.006_bib10","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2018.04.006_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"Meier","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.clon.2018.04.006_bib13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2018.04.006_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0090-8258(89)90168-6","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"34","author":"Morris","year":"1989","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.clon.2018.04.006_bib15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1993.11.3.434","article-title":"Secondary cytoreduction for ovarian cancer following cisplatin therapy","volume":"11","author":"Segna","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2018.04.006_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/IGC.0b013e31829f81ca","article-title":"Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome","volume":"23","author":"Fotopoulou","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.clon.2018.04.006_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0923-7534(20)31491-5","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clon.2018.04.006_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2011.01.014","article-title":"CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"121","author":"Fleming","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.clon.2018.04.006_bib20","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.clon.2018.04.006_bib21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","article-title":"Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis","volume":"16","author":"Harter","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.clon.2018.04.006_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/gyno.2001.6404","article-title":"Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma","volume":"83","author":"Scarabelli","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.20106","article-title":"Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?","volume":"100","author":"Zang","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clon.2018.04.006_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.clon.2018.04.006_bib25","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.clon.2018.04.006_bib26","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.clon.2018.04.006_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.clon.2018.04.006_bib28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib29","first-page":"3423","article-title":"AGO score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer","volume":"35","author":"Muallem","year":"2015","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.clon.2018.04.006_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2016.01.027","article-title":"Performance of AGO score for secondary cytoreduction in a high-volume U.S. center","volume":"141","author":"Janco","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.clon.2018.04.006_bib31","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","article-title":"Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation","volume":"20","author":"Fotopoulou","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.04.006_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2010.05.031","article-title":"The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas","volume":"119","author":"Chi","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.04.006_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2009.10.017","article-title":"Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer","volume":"46","author":"Gerestein","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clon.2018.04.006_bib34","first-page":"1591","article-title":"Surgery at primary versus relapsed epithelial ovarian cancer: a study on aspects of anaesthesiological management","volume":"35","author":"Feldheiser","year":"2015","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.clon.2018.04.006_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008765","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","author":"Galaal","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl","key":"10.1016\/j.clon.2018.04.006_bib36","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"du Bois","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518302358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:45:03Z","timestamp":1760543103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655518302358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0936655518302358"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2018.04.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When should Surgery be used for Recurrent Ovarian Carcinoma?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2018.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}